Keyphrases
Kinase Inhibitor
100%
Caenorhabditis Elegans
100%
Neurodegeneration
100%
Leucine-rich Repeat Kinase 2 (LRRK2)
100%
R1441C
21%
G2019S
15%
Kinase Activity
10%
Kinase Domain
10%
Parkinson's Disease
5%
In Vitro Activity
5%
Phosphorylation
5%
Therapeutic Potential
5%
Mutant Protein
5%
Therapeutic Strategies
5%
Transfected Cells
5%
Neuroprotective Effect
5%
Kinase Inhibition
5%
Neurotoxicity
5%
Neurodegenerative
5%
Inhibitor Resistant
5%
G2019S mutation
5%
Caenorhabditis Elegans Model
5%
Transgenic Worms
5%
Transgenic C. Elegans
5%
Small Molecule Targeting
5%
Late-onset Parkinson's Disease
5%
Behavioral Deficits
5%
Dopaminergic Deficit
5%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphotransferase Inhibitor
100%
Nerve Degeneration
100%
Leucine Rich Repeat Kinase 2
100%
Caenorhabditis Elegans
100%
Phosphotransferase
26%
Parkinson's Disease
10%
Dopamine Receptor Stimulating Agent
10%
Neuroprotective Agent
5%
Mutant Protein
5%
Neurotoxicity
5%
Neuroscience
Kinase
100%
Neurodegeneration
100%
Leucine Rich Repeat Kinase 2
100%
Caenorhabditis Elegans
100%
In Vitro
10%
Parkinson's Disease
10%
Dopaminergic
10%
In Vivo
5%
Neuroprotective Agent
5%
Neurotoxicity
5%
Mutant Protein
5%